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INTRODUCTION MLR-1023 (Tolimidone; 2(1H)-Pyrimidinone, 5-(3-methylphenoxy); see Figure 1 ) is a small orally bioavailable compound that was originally developed as an anti-ulcer therapeutic (Lipinski et al., 1980) . MLR-1023 reached Phase II clinical trials for this indication, exhibited good pharmacokinetic properties and was well-tolerated in patients when administered for up to 6 weeks (Saporito et al., 2012) . In a phenotypic screening platform designed to uncover new therapeutically beneficial activities of small molecules, MLR-1023 administration significantly lowered blood glucose in a mouse oral glucose tolerance test (OGTT) suggesting that it might be useful as a therapeutic for the treatment of type 2 diabetes (T2D) (Saporito et al., 2012) .
T2D is a heterogeneous disease of disrupted glucose homeostasis driven by insulin resistance, increased hepatic glucose output and pancreatic β cell dysfunction and loss (DeFronzo, 2010) . Oral drugs approved for the treatment of T2D are heterogeneous in their mechanisms, safety profiles and tolerability, with their utility limited by side-effect profile and/or limited efficacy (Krentz and Bailey, 2005; DeFronzo, 2010) . Among the new drugs in development for T2D are those that target protein kinases and kinase signaling pathways (Tahrani et al., 2011) , including selective kinase activators (Sanders et al., 2007; Viollet et al., 2007; Simpson et al., 2009; Eglen and Reisine, 2011) . Nearly all small molecule kinase activators act by binding to non-ATP allosteric binding sites on the target protein (Simpson et al., 2009; Eglen and Reisine, 2011) . These allosteric regulatory interactions confer a high degree of selectivity to kinase activators as This article has not been copyedited and formatted. The final version may differ from this version.
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Lyn kinase is a Src-related non-receptor linked tyrosine kinase that is found in an array of cell types and tissues including smooth muscle, liver, brain, myeloid cells and adipose tissue (Pertel et al., 2006; Scapini et al., 2009; Yamada et al., 2010; Gibb et al., 2011) .
Although Lyn kinase has been primarily studied in myeloid lineage cells, there are key data that implicate Lyn kinase as a regulator of insulin signaling and glucose regulation.
In adipocytes, Lyn kinase activation leads to a direct tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) Muller et al., 2001b) . IRS-1 phosphorylation amplifies the insulin receptor-signaling pathway by increasing Glut-4 translocation and glucose uptake and utilization Muller et al., 2001b; Muller et al., 2005) . This linkage between Lyn kinase activation and therapeutic efficacy in T2D has been noted for the oral diabetes therapeutic glimepiride (Muller, 2000; Muller et al., 2001a) . Glimepiride-mediated Lyn kinase activation activity may be responsible for glycemic control activity independent of its insulin-secretagogue activity (Muller, 2000; Muller et al., 2005) . However, glimepiride-mediated Lyn kinase activation occurs indirectly through regulation of lipid rafts and is likely to be non-specific (Muller et al., 2005) . A compound that directly activates Lyn kinase would provide a new therapeutic modality that would increase insulin-signaling events without affecting insulin secretion and promote glucose lowering effects that would be therapeutically beneficial in T2D.
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The present studies were designed to investigate the mechanisms involved in MLR-1023-mediated blood glucose lowering. These studies show that MLR-1023 selectively activated Lyn kinase through an allosteric mechanism in vitro, and that Lyn kinase activity is critical for MLR-1023-mediated blood glucose lowering activity in vivo.
METHODS

Materials
MLR-1023 was synthesized according to previously developed synthetic methods (Lipinski et al., 1980) 
Animals
All experiments were conducted in accordance with the National Institutes of Health regulations of animal care covered in "Principles of Laboratory Animal Care," National
Institutes of Health publication 85-23 and were approved by the Institutional Animal
Care and Use Committee
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JPET Fast Forward. Published on April 3, 2012 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from CD1-ICR male mice 8-10 weeks of age (Ace Animals, Boyertown, PA) were used in studies of baseline glucose, glucose tolerance and insulin levels. Male and female Lyn kinase knockout mice (129S4-Lyn tm1Sor /J) and wild-type controls (129S1/SvImJ) were acquired from Jackson Laboratories (Jackson, ME) (Chan et al., 1997) . At the time of study, Lyn kinase knockout mice were phenotypically similar to wild-type mice. Mice were fed a standard diet and were 8 weeks of age at time of study. Mice were housed 2-4 per cage and given free access to food and water unless otherwise noted. Animals were fed with Harlan Chow (2016 Teklad Global 16% Protein Rodent Diet).
Drug Administration
MLR-1023 was formulated in carboxymethyl cellulose (0.5%), Tween 80 (0.025%) in PBS. MLR-1023 was administered intraperitoneally (ip) at dose volumes of 5 to 10 mL/kg.
Oral glucose tolerance test and glucose measurements
For OGTT studies, mice were fasted for 18 hrs, treated with drug or vehicle and then given a glucose solution (1.5 g/kg) via oral gavage. Blood glucose levels were measured from a drop of blood (5 µL) that was collected from the tail. Blood glucose levels were measured prior to drug administration, prior to glucose challenge and at various times after glucose challenge.
Blood glucose levels were measured using Accu-Chek Aviva Glucometers (Roche Diagnostics) and levels reported as mg/dL. Glucometers were calibrated prior to each study. Blood (5 µL) was acquired from a tail snip and directly applied to a glucose test JPET #192096
strip. Blood levels of MLR-1023 were measured by LC/MS/MS and levels determined by comparing to a standard curve of MLR-1023 prepared in blood.
Serum Hormone Measurements
Serum was prepared from blood that was collected by retroorbital eyebleed. Insulin levels were measured from mouse serum using an "Ultra sensitive Mouse/Rat Insulin Elisa Kit" (Crystal Chem Inc., Downers Grove, IL) according to the manufacturer's directions.
In Vitro and Cell-Based Measurements
Studies of the effects of MLR-1023 on adipocyte differentiation, PPAR (α, δ , γ )
activation, DPP-IV activity, adiponectin production, insulin production, α -glucosidase inhibition and GLP-1 receptor activation were conducted at ChemBiotek (Kolkata, India).
All cell-based systems were validated with a reference compound (described for each assay below). The concentration of MLR-1023 was 10 μ M for all assays. Reference compound concentrations are described in Table 2 .
Briefly, adipocyte differentiation was assessed in mouse 3T3-L1 cells after 8 days of incubation with MLR-1023 or rosiglitazone (10 μ M) (Tamori et al., 2002; Li et al., 2007) .
Adiponectin production was measured in mouse 3T3-L1 cells after 6 days of incubation with MLR-1023 or rosiglitazone (10 μ M) (Xu et al., 2004 (Staels et al., 1998; Gervois et al., 1999; Raspe et al., 1999; Carmona et al., 2007) .
DPP-IV activity was assessed from protease derived from porcine kidney. MLR-1023 or P32/98 (10 μ M) was incubated in the presence of substrate (Gly-Pro-7-amido-4-methylcoumarin) for 30 minutes. Formation of the fluorescent proteolytic cleavage product was monitored as a measurement of DPP-IV activity (Kieffer et al., 1995) .
Insulin release was assessed in RINm5F cells. MLR-1023 or GLP-1 (5 μ M) was incubated with these cells for 60 minutes and insulin levels measured by ELISA (Jehle et al., 1995) . α -glucosidase activity was assessed from enzyme derived from Bacillus subtilis. This activity was measured by monitoring the cleavage of a p-nitrophenyl alpha-D-glucoside after 60-minute incubation with MLR-1023 or castanospermin (Ridruejo et al., 1989) . GLP-1 receptor activation was monitored by measuring cAMP production in RINm5F cells after incubation with MLR-1023 or GLP-1 (5 μ M) for 30 minutes (Watanabe et al., 1994) .
Kinase Assays
MLR-1023 was evaluated for activity against 47 separate kinases in a Caliper
Lifesciences kinase-profiling panel. The assay conditions for each kinase examined are The assays were conducted in duplicate.
Subsequent Lyn kinase assays were conducted with Upstate Ltd (Dundee, Scotland).
Briefly, MLR-1023 at concentrations ranging from 1 nM to 100 µM was preincubated with Lyn kinase (Upstate, recombinant human Lyn A, catalog # 14-510, batch #:
25111U; final concentration: 2 µg/mL), reaction buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM sodium orthovanadate, 0.1% 2-mercaptoethanol) and substrate Poly 
Data analysis
All data were analyzed by one or two-way ANOVA. A post-hoc Dunnett's or Bonferroni test was used to determine statistical differences between treatment groups. Data are expressed as the mean ± SEM, unless otherwise indicated. Group sizes ranged from 6 to 8 mice per group.
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In the OGTT study, glucose administration to fasted vehicle-treated mice evoked a 4-fold increase in blood glucose levels (56 to 227 mg/dL) with a peak increase observed 30 minutes after glucose challenge ( Figure 2C ). A single administration of MLR-1023 reduced blood glucose levels by 41% to 158 mg/dL. In this study, insulin levels did not increase but trended downward with MLR-1023 administration ( Figure 2D ).
Under these dosing conditions (ip; 30 mg/kg) MLR-1023 administration produced a C max level of 72.8 μM with a T max of 0.25 hrs ( Figure 2E ). Protein binding of MLR-1023 in mouse serum has been determined to be 99.0% (data not shown). Therefore the C max free plasma concentration of MLR-1023 can be estimated to be approximately 728 nM.
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Effects of MLR-1023 on targets and mechanisms associated with known diabetes therapeutics
In an effort to identify mechanisms that may be associated with MLR-1023-mediated blood glucose lowering, MLR-1023 was evaluated in a battery of in vitro and cell-based assays that represented mechanisms associated with T2D drugs and metabolic disease significantly increased adipocyte differentiation and adiponectin production by 3.7 and 19-fold, respectively. These increases; however, were far less than those elicited by rosiglitazone which increased these parameters by 21 and 140-fold, respectively. MLR-1023 elicited a concentration dependent increase in Lyn kinase activation with a 2.3 and 2.1-fold increase achieved at concentrations of 3 and 10 µM, respectively ( Figure   4B ). The data were analyzed by non-linear regression analysis using Graphpad Prism (version 5; San Diego, CA) was used to determine an EC 50 value. Using the log (agonist)
Evaluation of MLR-1023 in an
vs response curve fitting analysis and constraining the lower value to 100 (as this represents the control value) an EC 50 of 63 nM was generated. A similar concentration response curve was generated using concentrations ranging from 1-100 μM and under identical conditions. In that study, the effect at 100 μM did not differ from that of 3 or 10 μM (data not shown).
MLR-1023 mediated Lyn kinase activation: ATP kinetics
MLR-1023 mediated Lyn kinase activation was studied with increasing concentrations of ATP (range 6.25 to 800 µM). In control conditions (in the absence of MLR-1023), the rate of Lyn kinase activity increased with increasing ATP concentrations from 132 U/mg to 881 U/mg. Inclusion of MLR-1023 (100 µM) increased Lyn kinase activity by 3-fold at each ATP concentration tested (V max = 2,601 U/mg). MLR-1023 did not affect the K m for ATP (control= 22.4 µM; MLR-1023= 22.6 µM). These data are shown in Figure 5 .
Effects of MLR-1023 in Lyn kinase knockout mice
To further test the hypothesis that activation of Lyn kinase was responsible for the glucose lowering activity of MLR-1023, Lyn knockout mice were evaluated for blood This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on April 3, 2012 as DOI: 10.1124/jpet.112.192096 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from glucose levels after fasting, after an oral glucose challenge, and after administration of MLR-1023 and metformin ( Figure 6 ). In these studies, wild-type and Lyn knockout mice that were fasted for 18 hrs exhibited equivalent blood glucose levels (45.1 ± 4.2 compared to 47.4 ± 2.7 mg/dL, respectively). Likewise, oral glucose challenge produced an equivalent 4.5-fold increase in glucose levels (peak 224.2 ± 5.5 compared to 207.5 ± 8.6 mg/dL, respectively).
Acute administration of MLR-1023 (30 mg/kg) to wild-type mice treated with MLR-1023 showed a significant 35% reduction (MLR-1023=147.4 ± 11.8; Vehicle= 224.2 ± 5.5) in peak glucose on an OGTT compared to vehicle treated mice (p<0.05) ( Figure 6A ).
In contrast, MLR-1023-treated Lyn knockout mice exhibited equivalent peak blood glucose levels (201.2 ± 13.7 mg/dL) to those of vehicle-treated Lyn knockout mice (207.5 ± 8.7 mg/dL) ( Figure 6B ). In a separate study, administration of the gluconeogenesis inhibitor, metformin, to Lyn knockout mice produced an equivalent 55% blood glucose lowering compared to vehicle in both Lyn knockout mice and in wild-type mice ( Figure 6C and D) . The pharmacokinetic profiles of MLR-1023 in knockouts and wild-type mice were equivalent (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. (Simpson et al., 2009; Eglen and Reisine, 2011) . For example, the small molecule AMP kinase activator, PT-1, increases activity of the enzyme inhibiting the auto-inhibitory phosphorylation state of the enzyme (Pang et al., 2008) . Another AMP kinase activator, A-769,662 acts by binding to an allosteric binding site, inducing a conformational change that prevents dephosphorylation and inactivation of the kinase (Cool et al., 2006; Goransson et al., 2007) . There are also examples of small molecules directly activating a kinase through a conformational change independent of changing the phosphorylation state of the enzyme. For example, the insulin receptor tyrosine kinase activator L-783,281 and its structural analogs activate the enzyme by inducing a conformational change that removes auto-inhibition and allows ATP access to its binding site which in turn drives kinase activity (Zhang et al., 1999; Salituro et al., 2001) .
Lyn kinase activity is tightly controlled by its phosphorylation state (Donella-Deana et al., 1998; Ingley, 2008) . Phosphorylation of Lyn kinase at the Tyr397 residue within its activation loop results in increased activity (Donella-Deana et al., 1998) . In contrast, phosphorylation at the C-terminal tail Tyr 508 residue inhibits activity by inducing its association with an internal SH2 domain (Donella-Deana et al., 1998) . Lyn kinase is autophosphorylated at both sites (Ingley, 2008) . In addition, Lyn kinase can exist in a non-phosphorylated, partially active state (Ingley, 2008) . However, Lyn kinase is unlikely to exist in the non-phosphorylated form because of its propensity to autophosphorylate. Thus, it is unlikely that MLR-1023 induces a conformational change to the enzyme that shifts it to a fully activated non-phosphorylated form.
This article has not been copyedited and formatted. The final version may differ from this version. In these studies, MLR-1023 did not lower blood glucose levels in Lyn kinase knockout mice subjected to an OGTT. These data show that MLR-1023-mediated blood glucose lowering is dependent on the presence of Lyn kinase. Although these data do not necessarily indicate that MLR-1023 directly activates Lyn kinase in vivo, they do show a requirement of Lyn kinase for MLR-1023-mediated blood glucose lowering.
Interestingly, fasted blood glucose levels and peak glucose levels were equivalent in both wild-type and Lyn knockout mice, suggesting the presence of Lyn is not a requirement for maintaining glucose homeostasis. Further, metformin lowered glucose following a glucose challenge in both wild type and knockout animals showing that MLR-1023 and This article has not been copyedited and formatted. The final version may differ from this version.
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The known involvement of Lyn kinase in insulin signaling and the data from the current studies indicate that MLR-1023-mediates blood glucose lowering through a Lyn kinase dependent mechanism. Src-related kinases, and especially Lyn kinase, are directly involved in insulin signaling (Lebrun et al., 1998; Muller et al., 2001a; Muller et al., 2001b; Muller et al., 2005) . In adipocytes, activated Lyn kinase directly promotes the phosphorylation of IRS-1 and in turn promotes insulin signaling including Glut-4 translocation (Muller et al., 2001b; Muller et al., 2005) . However, the accompanying Glimepiride is a well-described insulin secretagogue that also promotes blood glucose lowering activity independent of its action on insulin secretion (Muller, 2000) .
Interestingly, this activity of glimepiride has also been related to activation of Lyn kinase JPET #192096 20 (Muller et al., 2001a; Muller et al., 2005) . However, unlike MLR-1023, this Lyn kinase activation is non-selective and indirectly regulated through effects on membrane associated lipid rafts (Muller et al., 2005) . Nevertheless, these data support the concept that activation of Lyn kinase is a viable mechanism for regulating blood glucose in T2D
patients.
The data generated from the current studies and the results shown in the accompanying The ATP concentration was 10 µM for both studies. To determine the EC 50 , data were analyzed by non-linear regression analysis with a log (agonist) vs response curve fitting and constraining the lower value to 100. The EC 50 for MLR-1023 was 63 nM. This article has not been copyedited and formatted. The final version may differ from this version.
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